Clinical Trial Update: A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities [Phase 3]

View source ↗

Summary

This completed Phase 3 trial evaluated tirzepatide (LY3298176) for maintenance of weight loss in adults with obesity or overweight and weight-related comorbidit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Tirzepatide (tirzepatide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Overweight, Obesity | Phase 3 | Status: COMPLETED